$0.01
(1.65%)
Add to watchlist
Create an alert
Stocks and Shares ISACASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.
Company Information
About this company
Key people
Wei-Wu He
Chairman of the Board, Chief Executive Officer
Daniel Lang
Chief Financial Officer, Senior Vice President
Chunhua Wang
Chief Operating Officer
Huang Hai
Global Chief Commercial Officer, Executive Vice President, General Manager of Casi China
Alexander A. Zukiwski
Executive Vice President, Chief Medical Officer
Wei Zhang
Senior Vice President
Kun Qian
Vice President, Global Controller
Wei Gao
General Counsel
Thomas Folinsbee
Independent Director
Zhenbo Su
Independent Director
Y. Alexander Wu
Independent Director
Xuebo Zeng
Independent Director
Click to see more
Key facts
- Shares in issue20.96m
- EPICCASI
- ISINKYG1933S1012
- LocationChina
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$17.44m
- Employees233
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.